Gut Bacteria Compound Linked to Increased Alzheimer’s Risk and Cognitive Decline

Recent findings indicate that imidazole propionate (ImP), a compound produced by gut bacteria, is linked to an increased risk of Alzheimer’s disease and accelerated cognitive decline. This relationship raises the potential for targeted interventions aimed at lowering ImP levels to mitigate dementia risk.

Want to explore the research behind this topic?Search the NPRL

Connection Between Gut Health and Alzheimer’s Disease

Researchers from the University of Wisconsin-Madison have discovered a connection between gut bacteria and Alzheimer’s disease by studying imidazole propionate (ImP). Prior investigations led by professors Barbara Bendlin and Federico Rey identified differences in gut microbiota composition between individuals with Alzheimer’s and healthy controls nearly ten years ago. Their continued efforts have focused on understanding how these variations could influence brain health.

ImP’s Role and Mechanism of Action

The new study, published in the journal Nature Communications, delves deeper into the implications of ImP. This molecule, which some gut bacteria synthesize, has recently been associated with enhancing brain changes characteristic of Alzheimer’s disease. The amount of ImP produced varies among individuals, with a significant proportion generating either high or low quantities. Rey noted that while ImP-producing bacteria may not be abundant in the microbiome, their presence can have considerable effects on overall health.

Once synthesized in the gut, ImP can enter the bloodstream and reach the brain, where it may influence the accumulation of beta amyloid and tau proteins — both associated with Alzheimer’s pathology. The results from experiments on mice indicated that elevated ImP levels could lead to neuron degeneration, a critical factor in the progression of Alzheimer’s.

Findings from Human Studies

The research team analyzed blood samples from nearly 1,200 individuals who participated in the Wisconsin Registry for Alzheimer’s Prevention.

Those with higher blood concentrations of ImP were significantly more likely to exhibit biological markers indicative of abnormal protein levels and impaired neuronal function.

Furthermore, cognitive assessments revealed that participants with elevated ImP levels experienced more rapid cognitive decline over time.

A genetic variation influencing ImP levels was identified in around 43% of the study population, which may impact the kidneys’ ability to filter out ImP, resulting in increased levels in the bloodstream. This genetic aspect has previously been linked to a higher Alzheimer’s risk, providing insight into the underlying mechanisms.

THE CNP TAKEAWAY

This study underscores the potential importance of gut-derived molecules like ImP in Alzheimer’s disease risk and cognitive decline. While dietary adjustments might not easily reduce ImP levels, targeted treatments could emerge from this research, aiming to mitigate Alzheimer’s risk for many individuals.